Tainan, Taiwan

Yu-Lin Leu


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yu-Lin Leu: Innovator in Anti-Cancer Prodrugs

Introduction

Yu-Lin Leu is a prominent inventor based in Tainan, Taiwan. She has made significant contributions to the field of cancer treatment through her innovative research and development of anti-cancer prodrugs. Her work focuses on enhancing the efficacy and safety of cancer therapies.

Latest Patents

Yu-Lin Leu holds a patent for BQC-G, a tumor-selective anti-cancer prodrug. This invention relates to the synthesis of a second-generation camptothecin glucuronide prodrug, which is derived from a potent anticancer camptothecin derivative known as 5,6-dihydro-4H-benzo[de]quinoline-camptothecin (BQC). BQC-G is over 4000 times more water-soluble than BQC and demonstrates good stability in human plasma. It serves as an excellent substrate for enzymatic hydrolysis by bacterial and human β-glucuronidases. Notably, BQC-G is approximately 30 times less toxic than BQC, but it exhibits similar toxicity to BQC after the hydrolysis of the glucuronide moiety by β-glucuronidase. In the presence of human serum albumin, BQC-G shows lower cytotoxicity (IC=1080 nM) but can be activated by β-glucuronidase to display potent activity (IC=13.3 nM).

Career Highlights

Yu-Lin Leu is affiliated with Academia Sinica, where she conducts her research. Her work has garnered attention for its potential to improve cancer treatment outcomes. She has successfully developed a prodrug that addresses the limitations of existing therapies, showcasing her innovative approach to drug design.

Collaborations

Yu-Lin Leu has collaborated with notable researchers, including Zeljko M Prijovic and Steve R Roffler. These collaborations have contributed to the advancement of her research and the development of her patented inventions.

Conclusion

Yu-Lin Leu is a trailblazer in the field of anti-cancer drug development. Her invention of BQC-G represents a significant advancement in cancer therapy, highlighting her dedication to improving patient outcomes. Her contributions to the scientific community continue to inspire future innovations in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…